Novelos Reports Positive Results From Phase II Ovarian Cancer Trial
Posted on: Thursday, 5 June 2008, 09:00 CDT
Novelos Therapeutics has reported encouraging results from a Phase II trial of NOV-002 in combination with carboplatin in platinum-resistant ovarian cancer patients.
In this open-label, single-arm Phase II trial, women with platinum-resistant ovarian cancer were treated with up to six cycles of NOV-002 and carboplatin. Efficacy endpoints included progression-free survival (PFS) and tumor response rate. Of 15 evaluable patients, 11 had previously failed three lines of chemotherapy, including platinum-based therapy. Tumors were assessed bi-monthly after at least eight weeks of treatment.
Median PFS was 15.4 weeks and mean PFS was 19.4 weeks. These values compare favorably to published data showing a median PFS of eight weeks in this late-stage, platinum-resistant patient population. Furthermore, five out of 15 women treated with NOV-002 and carboplatin had stable disease for five months (20 weeks) or longer.
In terms of best overall tumor response, one patient achieved a partial response, eight stable disease and six progressive disease. Thus, 60% (nine out of 15) women demonstrated clinical benefit and slowing of disease progression with NOV-002 and carboplatin. Hematologic toxicity was mild, suggesting possible mitigating effect of NOV-002. NOV-002 itself was also well-tolerated, further extending the excellent safety profile that NOV-002 has demonstrated in previous studies.
Harry Palmin, president and CEO of Novelos, said: "We are very pleased that NOV-002 continues to demonstrate activity in multiple tumor types, and we look forward to discussing with the FDA a design for a larger multi-center Phase II trial in ovarian cancer."
Source: Datamonitor
THE CLINIC Test Your Knowledge of the Conditions Behind the Health News This Week: Alzheimer's Disease
VA. On Alert Against Fatal Deer Disease ; Game Agency Activates Response Plan After Report of W.VA. Case
Cancer Vaccine Immune Response is Studied
Kaiser Permanente Wins Disease Management Award
New Noninvasive Pap Test for Breast May Identify Breast Disease Up to Eight Years Earlier
BG Medicine and Multiple Sclerosis Research Center of New York Announce Collaboration on Biomarker Discovery for MS Disease Activity and Drug Response
Med Officials Pleased With Responses for Partnership
Cimzia(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
Let's Put a Bite on Rabies: Keeping Pets Disease-Free an Owner's Responsibility
User Comments (0)
RSS Feeds